Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead
Corroborated by 1 source from 1 publisher
globalhealth3h ago
TL;DR
According to seekingalpha.com, arrowhead Pharmaceuticals (ARWR) received its first approval for plozasiran in November 2025, an siRNA therapy for Familial Chylomicronemia Syndrome (FCS) in adults.